West Pharmaceutical Services (WST)

As of 30 September 2026, short interest in WST is 2,101,162 shares, down 94,488 shares over the last month. Over the last 48 readings it ranged from 1,160,148 shares (13 December 2024) to 2,926,073 shares (31 March 2026). At the reported average volume of 675K shares a day that is 3.1 days to cover.

<iframe src="https://xoomar.com/embed/stocks/wst" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of WST volume is 50.3%, down 16.3 points over the last five sessions. Over the last 30 readings it ranged from 31.9% (28 September 2026) to 76.7% (7 October 2026). The latest reading is 4.2 points below the 30-session average of 54.5%, on 212K shares reported.

As of 8 September 2026, the fails-to-deliver balance in WST is 18 shares, down 62 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (19 May 2026) to 32,883 shares (30 June 2026). The latest reading sits at the bottom of that range.

Insiders at WST reported 6 open-market sells worth $5.4M in the last 90 days and no open-market buys. Latest filing: Favorite Annette F (Sr. VP & Chief HR Officer) on 2026-09-15.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

1 Form 144 notice on file for WST worth $1.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Hofmann Thomas W filed on 2026-05-07 to sell 3,384 shares ($1.1M) from 2026-05-07.

4 holders report 5% or more of WST in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (5,397,791 shares), filed 2026-04-30 for an event on 2026-03-31.

10 of the 30 tracked managers held WST at their latest 13F, $442.2M in total at quarter-end prices. Gates Foundation Trust is the largest at $159.6M (0.5% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 6 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) West Pharmaceutical Services reported revenue of $872.3M, up 13.8% from the same quarter a year earlier, and net income of $154.0M (2.15 diluted EPS). In FY 2025 it generated $754.8M of operating cash flow and spent $134.0M on buybacks and $61.2M on dividends. As of 2026-06-30, cash was $435.8M against $202.9M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-20 from the cover page.